We are live on ! Find out more
TDC

Thompson Davis & Co Portfolio holdings

AUM $150M
1-Year Est. Return 32.35%
This Fund
S&P 500
This Quarter Est. Return
+15.74%
1 Year Est. Return
+32.35%
3 Year Est. Return
+199.51%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$45.9M
AUM Growth
+$3.85M
Cap. Flow
-$689K
Cap. Flow %
-1.5%
Top 10 Hldgs %
19.46%
Holding
843
New
156
Increased
138
Reduced
151
Closed
116

Top Buys

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$350K
2
DIS icon
Walt Disney
DIS
+$321K
3
WMGI
Wright Medical Group Inc
WMGI
+$294K
4
T icon
AT&T
T
+$265K
5
ADT icon
ADT
ADT
+$263K

Top Sells

Rank Stock Value
1
CDNA icon
CareDx
CDNA
+$546K
2
AKTS
Akoustis Technologies Inc
AKTS
+$473K
3
VZ icon
Verizon
VZ
+$307K
4
VICR icon
Vicor
VICR
+$282K
5
KRE icon
State Street SPDR S&P Regional Banking ETF
KRE
+$265K

Sector Composition

Rank Sector Weight
1 Technology 18.7%
2 Healthcare 13.98%
3 Financials 8.19%
4 Industrials 8.17%
5 Consumer Discretionary 7.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABCD
651
DELISTED
Cambium Learning Group, Inc.
ABCD
$3K 0.01%
250
+125
+100% +$1.55K
MNTX
652
DELISTED
Manitex International, Inc.
MNTX
$3K 0.01%
250
-1,400
-85% -$16.3K
GCI
653
DELISTED
Gannett Co., Inc
GCI
$3K 0.01%
250
– –
CC icon
654
Chemours
CC
$2.59B
$2K ﹤0.01%
40
– –
CBUS icon
655
Cibus
CBUS
$130M
$2K ﹤0.01%
3
– –
CHI
656
Calamos Convertible Opportunities and Income Fund
CHI
$1.02B
$2K ﹤0.01%
162
– –
CORT icon
657
Corcept Therapeutics
CORT
$10.2B
$2K ﹤0.01%
125
– –
CTMX icon
658
CytomX Therapeutics
CTMX
$705M
$2K ﹤0.01%
125
– –
EEM icon
659
iShares MSCI Emerging Markets ETF
EEM
$28B
$2K ﹤0.01%
47
-14
-23% -$604
FCO
660
DELISTED
abrdn Global Income Fund
FCO
$2K ﹤0.01%
250
– –
GPMT
661
Granite Point Mortgage Trust
GPMT
$63.7M
$2K ﹤0.01%
125
– –
GS icon
662
Goldman Sachs
GS
$313B
$2K ﹤0.01%
10
– –
HALO icon
663
Halozyme
HALO
$9.72B
$2K ﹤0.01%
125
– –
HOG icon
664
Harley-Davidson
HOG
$2.68B
$2K ﹤0.01%
50
– –
HPE icon
665
Hewlett Packard
HPE
$63.2B
$2K ﹤0.01%
100
– –
KGC icon
666
Kinross Gold
KGC
$28.5B
$2K ﹤0.01%
617
– –
KPTI icon
667
Karyopharm Therapeutics
KPTI
$168M
$2K ﹤0.01%
8
– –
MXL icon
668
MaxLinear
MXL
$6.49B
$2K ﹤0.01%
125
-250
-67% -$4.55K
NX icon
669
Quanex
NX
$854M
$2K ﹤0.01%
+125
New +$2.2K
OPTN
670
DELISTED
OptiNose
OPTN
$2K ﹤0.01%
8
-242
-97% -$69K
ORCL icon
671
Oracle
ORCL
$331B
$2K ﹤0.01%
34
– –
PGEN icon
672
Precigen
PGEN
$1.93B
$2K ﹤0.01%
+125
New +$1.86K
REI icon
673
Ring Energy
REI
$322M
$2K ﹤0.01%
250
– –
RING icon
674
iShares MSCI Global Gold Miners ETF
RING
$2.31B
$2K ﹤0.01%
125
– –
SMPL icon
675
Simply Good Foods
SMPL
$904M
$2K ﹤0.01%
+125
New +$2.17K
25 26
27
28 29

Similar funds

PAYA
Phil A. Younker & Associates Fairbanks, Alaska $150M AUM 9.85% 1-Year Est. Return
PCMNC
Piedmont Capital Management (North Carolina) Greensboro, North Carolina $150M AUM
LA
Lakeside Advisors Seattle, Washington $150M AUM 14.73% 1-Year Est. Return
MPW
Magnolia Private Wealth Philadelphia, Pennsylvania $150M AUM 18.29% 1-Year Est. Return
GWA
Genesis Wealth Advisors Braintree, Massachusetts $150M AUM 15.35% 1-Year Est. Return
GA
Gordian Advisors Tucson, Arizona $150M AUM 15.35% 1-Year Est. Return
RPA
Redwood Park Advisors Redwood City, California $150M AUM 11.34% 1-Year Est. Return
E
Evansbrook Bolingbrook, Illinois $150M AUM

Thompson Davis & Co's Q3 2018 Portfolio in Review

As of Q3 2018, Thompson Davis & Co held 843 positions worth $45.9M, up 9.2% from $42M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Thompson Davis & Co's Q3 2018 filing shows 156 new, 138 increased, 151 reduced and 116 closed positions. Its largest new stake was Globus Medical: 6,660 shares worth $378K. The largest sale was CareDx, an estimated $546K.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.

  • Thompson Davis & Co's largest Q3 2018 buy was Globus Medical: 6,660 shares worth $378K.
  • Thompson Davis & Co added most to Walt Disney in Q3 2018, an estimated $321K increase.
  • Thompson Davis & Co's biggest Q3 2018 reduction was CareDx, cutting an estimated $546K.
  • Thompson Davis & Co fully exited Vicor in Q3 2018, selling an estimated $282K.
  • Thompson Davis & Co's ten largest holdings make up 19% of its $45.9M portfolio in Q3 2018.
  • Thompson Davis & Co opened 156 new positions and closed 116 in Q3 2018.
  • Thompson Davis & Co's portfolio value rose 9.2% quarter-over-quarter to $45.9M.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.